SCHEMBL1067997

SCHEMBL1067997

Cn1cc(Br)nc(Nc2ccc(CO)cc2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.38
CREBBP Q92793 1/20 0.37
SYK P43405 4/20 0.36
BPTF Q12830 1/20 0.36
KAT2B Q92831 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
BTK Q06187 3/20 0.35
PYGM P11217 2/20 0.33
TYR P14679 1/20 0.33
MAP4K4 O95819 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
ABL1 P00519 1/20 0.32
PDGFRB P09619 1/20 0.32
SRC P12931 1/20 0.32
PDGFRA P16234 1/20 0.32
MAPK14 Q16539 1/20 0.32
P2RX3 P56373 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065221 0.90 ABL1 (0.41) BRD4SYKBPTFKAT2BBRD9
SCHEMBL15886528 0.81 BRD4 (0.43) BRD4BPTFKAT2BBRD9BTK
SCHEMBL15886525 0.81 RAB9A (0.43) BTKMAPT
SCHEMBL1432103 0.81 GSK3B (0.45) MAPT
SCHEMBL1069892 0.80 GAA (0.40) BRD4BTKPYGMMAPT
SCHEMBL15886453 0.79 MEN1 (0.44) BRD4CREBBPBTKPYGM
SCHEMBL1432525 0.78 JAK2 (0.46) SYKBTKPDGFRA
SCHEMBL14472559 0.78 DHODH (0.41) BRD4CREBBPSYKBRD9P2RX3
SCHEMBL1067111 0.78 RAB9A (0.51) MAPTTHRB
SCHEMBL15886527 0.76 KMT2A (0.49) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863766-B1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT INC (US) 2015-05-20 EP disclosed
US-8536166-B2 Inhibitors of Burton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2013-09-17 US disclosed
US-8536166-B2 Inhibitors of Burton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2013-09-17 US disclosed
EP-2300459-B1 NOVEL PHENYLPYRAZINONES AS KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2013-05-29 EP disclosed
US-7947835-B2 Certain substituted amides, method of making, and method of use thereof CGI PHARMACEUTICALS, INC. (US) 2011-05-24 US disclosed
US-7947835-B2 Certain substituted amides, method of making, and method of use thereof CGI PHARMACEUTICALS, INC. (US) 2011-05-24 US disclosed
US-7947835-B2 Certain substituted amides, method of making, and method of use thereof CGI PHARMACEUTICALS, INC. (US) 2011-05-24 US disclosed
EP-2300459-A1 NOVEL PHENYLPYRAZINONES AS KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-03-30 EP disclosed
EP-2270200-A2 Kinase inhibitors, and methods of using and identifying kinase inhibitors CGI Pharmaceuticals, Inc. (US) 2011-01-05 EP disclosed
EP-2270200-A2 Kinase inhibitors, and methods of using and identifying kinase inhibitors CGI Pharmaceuticals, Inc. (US) 2011-01-05 EP disclosed
US-20100160292-A1 Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors CGI PHARMACEUTICALS, INC (US) 2010-06-24 US disclosed
US-20100004231-A1 INHIBITORS OF BURTON'S TYROSINE KINASE ROCHE PALO ALTO LLC 2010-01-07 US disclosed
US-20100004231-A1 INHIBITORS OF BURTON'S TYROSINE KINASE ROCHE PALO ALTO LLC 2010-01-07 US disclosed
WO-2010000633-A1 NOVEL PHENYLPYRAZINONES AS KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-07 WO disclosed
EP-2068849-A2 KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS CGI Pharmaceuticals, Inc. (US) 2009-06-17 EP disclosed
WO-2008033858-A2 KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2008-03-20 WO disclosed
WO-2008033858-A2 KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2008-03-20 WO disclosed
EP-1863766-A2 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI Pharmaceuticals, Inc. (US) 2007-12-12 EP disclosed
US-20060229337-A1 Certain substituted amides, method of making, and method of use thereof GILEAD CONNECTICUT, INC. 2006-10-12 US disclosed
WO-2006099075-A2 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160292-A1 Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors BTK, LYN, LCK BRD4 575/4885CREBBP 681/4885SYK 4/4885
US-20060229337-A1 Certain substituted amides, method of making, and method of use thereof BTK, SYK, MYD88 BRD4 187/4885CREBBP 387/4885SYK 2/4885
US-20100004231-A1 INHIBITORS OF BURTON'S TYROSINE KINASE BTK, LCK, LYN BRD4 397/4885CREBBP 1016/4885SYK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.